Januvia, Galvus, Onglyza and Trajenta vie for market share in Korea

Multinational pharmaceutical companies will step up their marketing in the domestic dipeptidyl peptidase-IV (DPP-IV) inhibitors market dominated by Merck’s Januvia (sitagliptin) and Novartis’s Galvus (vildagliptin), which is expected to become more competitive than ever late this year, according to industry sources.

Developed by BMS/AstraZeneca, Onglyza (saxagliptin) is a smaller pill - thus...